Meeting
2018 Gastrointestinal Cancers Symposium
Panitumumab versus cetuximab in patients with wild-type KRAS exon 2 metastatic colorectal cancer who received prior bevacizumab therapy: A combined analysis of individual patient data from ASPECCT and WJOG6510G.
Authors
Hiroya Taniguchi
Aichi Cancer Center Hospital, Nagoya, Japan
Hiroya Taniguchi , Takeharu Yamanaka , Daisuke Sakai , Kentaro Yamazaki , Kei Muro , Marc Peeters , Timothy Jay Price
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Cancers of the Colon, Rectum, and Anus
Track
Cancers of the Colon, Rectum, and Anus
Sub Track
Multidisciplinary Treatment
Citation
J Clin Oncol 36, 2018 (suppl 4S; abstr 745)
DOI
10.1200/JCO.2018.36.4_suppl.745
Abstract #
745
Poster Bd #
J11
Abstract Disclosures
Similar Posters
Poster
2016 ASCO Annual Meeting
Efficacy of panitumumab vs cetuximab in patients with wild-type KRAS exon 2 metastatic colorectal cancer treated with prior bevacizumab: Results from ASPECCT.
First Author: Marc Peeters
Poster
2016 Gastrointestinal Cancers Symposium
Efficacy of panitumumab (pmab) vs. cetuximab (cmab) in patients (pts) with wild-type (WT) KRAS exon 2 metastatic colorectal cancer (mCRC) treated with prior bevacizumab (bev): Results from ASPECCT.
First Author: Marc Peeters
Poster
2016 Gastrointestinal Cancers Symposium
Outcomes by hypomagnesemia (hypomag) in the randomized phase III ASPECCT trial of patients (pts) with chemofractory wild-type (WT) KRAS exon 2 metastatic colorectal cancer (mCRC).
First Author: Marc Peeters
Poster
2015 ASCO Annual Meeting
Randomized phase 3 study of panitumumab (pmab) vs cetuximab (cmab) in chemorefractory wild-type (WT) KRAS exon 2 metastatic colorectal cancer (mCRC): outcomes by hypomagnesemia (hypomag) in ASPECCT.
First Author: Marc Peeters